Fairmount Funds Management LLC
- SEC CIK
- 0001802528
- Latest filing
- Aug 14, 2026
Holdings in Q2 2022
Holdings as of Jun 30, 2022, filed Aug 15, 2022. Long positions only; changes compare share counts with Q1 2022.
- Positions
- 27
- +5 vs. Q1 2022
- Portfolio value
- $436.9M
- +$14.0M (+3.3%) vs. Q1 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| BHVNBiohaven Ltd. | COM | 264,206 | $38.5M | 8.8% | +24,892+10.4% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 942,571 | $36.1M | 8.3% | 00.0% | Unchanged | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 3,343,107 | $35.4M | 8.1% | +3,343,107 | New | History |
| GBTGlobal Blood Therapeutics, Inc. | COM | 953,396 | $30.5M | 7.0% | −228,911−19.4% | Reduced | History |
| ARGXArgenx SE | SPONSORED ADR | 73,526 | $27.9M | 6.4% | −50,718−40.8% | Reduced | History |
| NBIXNeurocrine Biosciences Inc | Stock | 283,000 | $27.6M | 6.3% | +283,000 | New | History |
| INSMINSMED Inc | COM PAR $.01 | 1,326,368 | $26.2M | 6.0% | −622,416−31.9% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 2,758,975 | $24.9M | 5.7% | +1,200,000+77.0% | Added | History |
| NUVLNuvalent, Inc. | COM | 1,715,518 | $23.3M | 5.3% | +377,125+28.2% | Added | History |
| ENTAEnanta Pharmaceuticals Inc | COM | 469,264 | $22.2M | 5.1% | 00.0% | Unchanged | History |
| ONCBeOne Medicines Ltd. | ADR | 111,400 | $18.0M | 4.1% | +111,400 | New | History |
| CTICCti Biopharma Corp | COM | 2,245,891 | $13.4M | 3.1% | +2,245,891 | New | History |
| PNTPOINT Biopharma Global Inc. | COM | 1,833,950 | $12.5M | 2.9% | −478,573−20.7% | Reduced | History |
| DBVTDBV Technologies S.A. | SPONSORED ADR | 4,831,155 | $12.3M | 2.8% | +4,831,155 | New | History |
| VRDNViridian Therapeutics, Inc. | COM | 944,092 | $10.9M | 2.5% | 00.0% | Unchanged | History |
| ANNXAnnexon, Inc. | COM | 2,892,600 | $10.9M | 2.5% | +1,643,457+131.6% | Added | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 2,669,300 | $10.9M | 2.5% | 00.0% | Unchanged | History |
| ACADAcadia Pharmaceuticals Inc | COM | 751,804 | $10.6M | 2.4% | −405,013−35.0% | Reduced | History |
| TYRATyra Biosciences, Inc. | COM | 1,416,998 | $10.1M | 2.3% | +132,008+10.3% | Added | History |
| AMRNAmarin Corp PLC | SPONS ADR NEW | 5,584,837 | $8.32M | 1.9% | +1,451,600+35.1% | Added | History |
| KROSKeros Therapeutics, Inc. | COM | 272,498 | $7.53M | 1.7% | −124,413−31.3% | Reduced | History |
| TRVITrevi Therapeutics, Inc. | COM | 1,624,389 | $4.57M | 1.0% | +1,624,389 | New | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 389,588 | $4.30M | 1.0% | 00.0% | Unchanged | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 926,602 | $3.88M | 0.9% | 00.0% | Unchanged | History |
| TILInstil Bio, Inc. | COM | 673,905 | $3.11M | 0.7% | 00.0% | Unchanged | History |
| ATXSAstria Therapeutics, Inc. | COM | 911,736 | $2.73M | 0.6% | 00.0% | Unchanged | History |
| ALLKAllakos Inc. | COM | 147,189 | $461.0K | 0.1% | 00.0% | Unchanged | History |
Sold out since Q1 2022 (1)
Positions held at the end of Q1 2022 that are gone from this filing.